MedTrace Logo

Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT07682376 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2026-07-02

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of neoadjuvant low-dose radiotherapy combined with Retlirafusp alfa and chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma.

Conditions

  • Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG

Low-dose radiotherapy + Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin

Low-dose radiotherapy: 8 Gy in 4 fractions, 2 Gy per fraction, targeting the primary tumor and metastatic lymph nodes. Retlirafusp alfa: 1800 mg or 30 mg/kg on D1, q3w, for 2 cycles. Nab-paclitaxel: 125 mg/m² on D1 and D8, plus cisplatin 75 mg/m² on D1 or carboplatin AUC=5 on D1, q3w, for 2 cycles.

DRUG

Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin

Retlirafusp alfa: 1800 mg or 30 mg/kg on D1, q3w, for 2 cycles. Nab-paclitaxel: 125 mg/m² on D1 and D8, plus cisplatin 75 mg/m² on D1 or carboplatin AUC=5 on D1, q3w, for 2 cycles.

Sponsors & Collaborators

  • Henan Cancer Hospital

    collaborator OTHER_GOV

  • Shanxi Province Cancer Hospital

    collaborator OTHER

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Harbin Medical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-10
Primary Completion
2028-05-30
Completion
2029-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07682376 on ClinicalTrials.gov